Senellart H, Bennouna J
Centre René Gauducheau, Nantes, France.
Rev Mal Respir. 2008 Oct;25(8):1027-30. doi: 10.1016/s0761-8425(08)74418-8.
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. The use of bevacizumab has shown survival benefit in variety of cancers. However, a specific toxicity profile has been observed with bevacizumab such as hypertension, proteinuria, gastrointestinal perforation and arterial thrombosis. Non-small-cell lung cancer is often associated with thrombotic event therefore guidelines are expected to prescribe bevacizumab in this population. This article presents data from literature about the thrombotic risk and provides recommendations for the use of anticoagulant and antiaggregant treatments.
贝伐单抗是一种抗血管内皮生长因子的单克隆抗体。使用贝伐单抗已在多种癌症中显示出生存获益。然而，已观察到贝伐单抗具有特定的毒性特征，如高血压、蛋白尿、胃肠道穿孔和动脉血栓形成。非小细胞肺癌常与血栓形成事件相关，因此预计指南会对该人群开具贝伐单抗处方。本文介绍了文献中关于血栓形成风险的数据，并提供了使用抗凝和抗血小板治疗的建议。
